FRM
CRSP icon

Fox Run Management’s CRISPR Therapeutics CRSP Stock Holding History

Fox Run Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,473
Closed -$629K – 934
2025
Q1 		$629K Buy
+18,473
New +$783K 0.1% 391
2023
Q4 		– Sell
-4,511
Closed -$205K – 771
2023
Q3 		$205K Sell
4,511
-2,325
-34% -$120K 0.06% 557
2023
Q2 		$384K Buy
+6,836
New +$388K 0.11% 360
2020
Q1 		– Sell
-5,334
Closed -$325K – 169
2019
Q4 		$325K Buy
+5,334
New +$291K 0.26% 157
2018
Q3 		– Sell
-11,347
Closed -$667K – 618
2018
Q2 		$667K Buy
+11,347
New +$646K 0.21% 150

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fox Run Management's CRSP Position: Q2 2025 in Review

Fox Run Management sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 18,473 shares — an estimated $629K sold.

Fox Run Management first reported a position in CRSP in Q2 2018 and held it in 5 quarters. The position peaked at $667K in Q2 2018. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Fox Run Management reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 18,473 CRISPR Therapeutics shares in Q2 2025, an estimated $629K.
  • Fox Run Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 5 quarters.
  • Fox Run Management's CRISPR Therapeutics position peaked at $667K in Q2 2018.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.